HBIO vs ITRN vs BEAT vs MLAB vs XPER

For growth investors, Mesa Laboratories, Inc.

(MLAB) is the stronger pick with 11. 5% revenue growth year-over-year, versus -9. 2% for Xperi Inc. (XPER). Ituran Location and Control Ltd. (ITRN) offers the better valuation at 20. 2x trailing P/E (17. 8x forward), making it the more compelling value choice. Analysts rate Harvard Bioscience, Inc. (HBIO) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Xperi Inc.

is actually cheaper at 7. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Ituran Location and Control Ltd.

(ITRN) delivered a total return of +180. 2%, compared to -90. 7% for Harvard Bioscience, Inc. (HBIO). Over 10 years, the gap is even starker: ITRN returned +233. 6% versus BEAT's -81. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ituran Location and Control Ltd.

(ITRN) is the lower-risk stock at 1. 18β versus Harvard Bioscience, Inc. 's 2. 03β — meaning HBIO is approximately 73% more volatile than ITRN relative to the S&P 500. On balance sheet safety, Ituran Location and Control Ltd. (ITRN) carries a lower debt/equity ratio of 2% versus 3% for Harvard Bioscience, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Mesa Laboratories, Inc.

(MLAB) is pulling ahead at 11. 5% versus -9. 2% for Xperi Inc. (XPER). On earnings-per-share growth, the picture is similar: Mesa Laboratories, Inc. grew EPS 99. 2% year-over-year, compared to -357. 1% for Harvard Bioscience, Inc.. Over a 3-year CAGR, MLAB leads at 9. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Ituran Location and Control Ltd.

(ITRN) is the more profitable company, earning 16. 1% net margin versus -65. 5% for Harvard Bioscience, Inc. — meaning it keeps 16. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ITRN leads at 21. 4% versus -9. 8% for XPER. At the gross margin level — before operating expenses — XPER leads at 71. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Xperi Inc.

(XPER) trades at 7. 9x forward P/E versus 17. 8x for Ituran Location and Control Ltd. — 9. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ITRN: -5. 0% to $56. 00.

In this comparison, ITRN (3.

2% yield), XPER (2. 5% yield), MLAB (0. 6% yield) pay a dividend. HBIO, BEAT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Ituran Location and Control Ltd.

(ITRN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 18), 3. 2% yield, +233. 6% 10Y return). Harvard Bioscience, Inc. (HBIO) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ITRN: +233. 6%, HBIO: -76. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HBIO (Healthcare) and ITRN (Technology) and BEAT (Healthcare) and MLAB (Technology) and XPER (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HBIO is a small-cap quality compounder stock; ITRN is a small-cap income-oriented stock; BEAT is a small-cap quality compounder stock; MLAB is a small-cap quality compounder stock; XPER is a small-cap quality compounder stock. ITRN, MLAB, XPER pay a dividend while HBIO, BEAT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.